JP2023530600A - 細胞外ベシクルの製造するための方法及びその使用 - Google Patents

細胞外ベシクルの製造するための方法及びその使用 Download PDF

Info

Publication number
JP2023530600A
JP2023530600A JP2022573448A JP2022573448A JP2023530600A JP 2023530600 A JP2023530600 A JP 2023530600A JP 2022573448 A JP2022573448 A JP 2022573448A JP 2022573448 A JP2022573448 A JP 2022573448A JP 2023530600 A JP2023530600 A JP 2023530600A
Authority
JP
Japan
Prior art keywords
evs
cells
protein
antibody
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530600A5 (enExample
Inventor
ジェームズ トーマス ケルバー，
ヨンリャン スン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023530600A publication Critical patent/JP2023530600A/ja
Publication of JP2023530600A5 publication Critical patent/JP2023530600A5/ja
Priority to JP2025173693A priority Critical patent/JP2026027260A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
JP2022573448A 2020-06-01 2021-05-31 細胞外ベシクルの製造するための方法及びその使用 Pending JP2023530600A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025173693A JP2026027260A (ja) 2020-06-01 2025-10-15 細胞外ベシクルの製造するための方法及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063033014P 2020-06-01 2020-06-01
US63/033,014 2020-06-01
PCT/US2021/035072 WO2021247457A2 (en) 2020-06-01 2021-05-31 Methods for making extracellular vesicles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025173693A Division JP2026027260A (ja) 2020-06-01 2025-10-15 細胞外ベシクルの製造するための方法及びその使用

Publications (2)

Publication Number Publication Date
JP2023530600A true JP2023530600A (ja) 2023-07-19
JP2023530600A5 JP2023530600A5 (enExample) 2024-06-10

Family

ID=76943084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022573448A Pending JP2023530600A (ja) 2020-06-01 2021-05-31 細胞外ベシクルの製造するための方法及びその使用
JP2025173693A Pending JP2026027260A (ja) 2020-06-01 2025-10-15 細胞外ベシクルの製造するための方法及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025173693A Pending JP2026027260A (ja) 2020-06-01 2025-10-15 細胞外ベシクルの製造するための方法及びその使用

Country Status (13)

Country Link
US (1) US20230090177A1 (enExample)
EP (1) EP4157866A2 (enExample)
JP (2) JP2023530600A (enExample)
KR (1) KR20230017822A (enExample)
CN (1) CN115667294A (enExample)
AR (1) AR122496A1 (enExample)
AU (1) AU2021285802A1 (enExample)
BR (1) BR112022024472A2 (enExample)
CA (1) CA3182473A1 (enExample)
IL (1) IL298599A (enExample)
MX (1) MX2022014892A (enExample)
TW (2) TWI885439B (enExample)
WO (1) WO2021247457A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023264069A1 (en) 2022-05-03 2024-10-24 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
CN115845083B (zh) * 2022-12-12 2025-04-11 南京逸微健华生物科技有限公司 一种靶向改造Expi293细胞外泌体递送siMMP13的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
JP2006518212A (ja) * 2003-02-14 2006-08-10 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
WO2017175253A1 (ja) * 2016-04-04 2017-10-12 国立研究開発法人医薬基盤・健康・栄養研究所 エキソソーム標的ｄｎａワクチン
JP2019017341A (ja) * 2017-07-20 2019-02-07 国立研究開発法人国立がん研究センター 標識小胞及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (enExample) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2013119602A1 (en) * 2012-02-06 2013-08-15 President And Fellows Of Harvard College Arrdc1-mediated microvesicles (armms) and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
JP2006518212A (ja) * 2003-02-14 2006-08-10 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
WO2017175253A1 (ja) * 2016-04-04 2017-10-12 国立研究開発法人医薬基盤・健康・栄養研究所 エキソソーム標的ｄｎａワクチン
JP2019017341A (ja) * 2017-07-20 2019-02-07 国立研究開発法人国立がん研究センター 標識小胞及びその製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL MOL NEUROBIOL., vol. 36, JPN6025014384, 2016, pages 301 - 312, ISSN: 0005787214 *
MOL BIOL CELL., vol. 17, JPN6025014386, 2006, pages 3469 - 3483, ISSN: 0005787215 *
PROTEOMICS, vol. Vol. 18, Issue 17, 1800266, JPN6025014383, 2018, pages 1 - 6, ISSN: 0005787213 *
ウイルス, vol. 第52巻, 第1号, JPN6025014382, 2002, pages 95 - 102, ISSN: 0005787212 *

Also Published As

Publication number Publication date
WO2021247457A2 (en) 2021-12-09
MX2022014892A (es) 2023-01-04
AR122496A1 (es) 2022-09-14
JP2026027260A (ja) 2026-02-18
EP4157866A2 (en) 2023-04-05
KR20230017822A (ko) 2023-02-06
TW202423962A (zh) 2024-06-16
CA3182473A1 (en) 2021-12-09
WO2021247457A3 (en) 2022-01-13
TWI814008B (zh) 2023-09-01
AU2021285802A1 (en) 2022-12-08
TWI885439B (zh) 2025-06-01
US20230090177A1 (en) 2023-03-23
IL298599A (en) 2023-01-01
BR112022024472A2 (pt) 2022-12-27
CN115667294A (zh) 2023-01-31
TW202204414A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
JP7333104B2 (ja) Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用
AU2012248470B2 (en) Anti-B7-H3 antibody
US11873337B2 (en) Antibody binding to cell adhesion molecule 3
JP2026027260A (ja) 細胞外ベシクルの製造するための方法及びその使用
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
CN118667021A (zh) 紧密连接蛋白6抗体和治疗癌症的方法
JP2011506387A (ja) 抗原結合タンパク質
AU2019295277B2 (en) Antibody binding to chondroitin sulfate proteoglycan-5
WO2021043206A1 (zh) 一种抗tigit免疫抑制剂及应用
JP2024512574A (ja) Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
CN110809582A (zh) 涉及抗pd1抗体试剂的方法以及组合物
KR20210071987A (ko) 항-cd79 항체 및 이들의 용도
CN111201031A (zh) 抗CD47 x抗间皮素抗体及其使用方法
US20240390418A1 (en) Anti-variable muc1* antibodies and uses thereof
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
HK40082432A (en) Methods for making extracellular vesicles and uses thereof
JPWO2016143702A1 (ja) 抗ヒト膜型ａｄａｍ２８抗体
WO2023064435A2 (en) Compositions and methods relating to sars-cov-2 neutralizing antibodies
RU2790326C2 (ru) Анти-сd3-антитело и молекула, содержащая это антитело
CN118994391A (zh) 特异性结合cd38的抗体及其制法和应用
CN121736103A (zh) 抗folr1抗体及其应用
TW201927336A (zh) 細胞毒性ｔ細胞耗竭用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203